The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days […]readmore
Tags : Bristol-Myers Squibb
Shots: The collaboration will evaluate Nektar Therapeutics’ bempegaldesleukin in combination with BMS’ Opdivo (nivolumab) into multiple new registrational trials and the cost of trials will be shared upon the cost-sharing […]readmore
Shots: Evotec to receive $6M payment from BMS to expand its partnership with the inclusion of additional cell lines In 2016, Evotec signed a 5-year research agreement with Celgene (now […]readmore
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were […]readmore
Healthcare, pharmaceutical, and biotech companies are gearing up to tap new markets as they look to consolidate their positions after a spate of mergers & acquisitions and licensing partnerships in […]readmore
Shots: BMS plans to divest Otezla to address US Federal Trade Commission concern to close pending Celgene acquisition for $74B more quickly In Jan’2019, BMS announced to acquire Celgene with […]readmore
Shots: The P-III CheckMate-459 study results involve assessing of Opdivo vs sorafenib as a 1L treatment in patients with unresectable hepatocellular carcinoma (HCC) The P-III CheckMate-459 study results demonstrated that […]readmore
Shots: Catalent to purchase BMS’ oral solid, biologics, and sterile product manufacturing and packaging facility and will continue to manufacture BMS’s current product portfolio at the site, providing facilities in […]readmore
In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and […]readmore
The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top […]readmore